IHT Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $758K | Buy |
1,697
+234
| +16% | +$109K | 0.02% | 668 |
|
|
2025
Q4 | $663K | Sell |
1,463
-79
| -5% | -$34.1K | 0.02% | 668 |
|
|
2025
Q3 | $604K | Sell |
1,542
-5
| -0.3% | -$2.09K | 0.02% | 680 |
|
|
2025
Q2 | $689K | Buy |
1,547
+5
| +0.3% | +$2.3K | 0.02% | 606 |
|
|
2025
Q1 | $747K | Sell |
1,542
-242
| -14% | -$113K | 0.02% | 550 |
|
|
2024
Q4 | $718K | Sell |
1,784
-747
| -30% | -$346K | 0.02% | 557 |
|
|
2024
Q3 | $1.18M | Buy |
2,531
+467
| +23% | +$224K | 0.03% | 459 |
|
|
2024
Q2 | $967K | Sell |
2,064
-51
| -2% | -$22.1K | 0.04% | 445 |
|
|
2024
Q1 | $884K | Buy |
2,115
+337
| +19% | +$142K | 0.04% | 464 |
|
|
2023
Q4 | $723K | Buy |
1,778
+36
| +2% | +$13.3K | 0.03% | 488 |
|
|
2023
Q3 | $606K | Sell |
1,742
-60
| -3% | -$21K | 0.03% | 493 |
|
|
2023
Q2 | $634K | Sell |
1,802
-141
| -7% | -$47.5K | 0.03% | 470 |
|
|
2023
Q1 | $612K | Sell |
1,943
-70
| -3% | -$21K | 0.03% | 446 |
|
|
2022
Q4 | $581K | Sell |
2,013
-212
| -10% | -$64.6K | 0.04% | 443 |
|
|
2022
Q3 | $644K | Buy |
+2,225
| New | +$640K | 0.05% | 384 |
|
|
2022
Q2 | – | Sell |
-1,838
| Closed | -$480K | – | 810 |
|
|
2022
Q1 | $480K | Sell |
1,838
-2,428
| -57% | -$576K | 0.04% | 421 |
|
|
2021
Q4 | $937K | Sell |
4,266
-522
| -11% | -$102K | 0.07% | 277 |
|
|
2021
Q3 | $868K | Sell |
4,788
-1,459
| -23% | -$285K | 0.07% | 275 |
|
|
2021
Q2 | $1.26M | Buy |
6,247
+619
| +11% | +$129K | 0.08% | 271 |
|
|
2021
Q1 | $1.21M | Buy |
5,628
+556
| +11% | +$122K | 0.09% | 239 |
|
|
2020
Q4 | $1.2M | Buy |
5,072
+2,429
| +92% | +$557K | 0.1% | 213 |
|
|
2020
Q3 | $719K | Sell |
2,643
-1,817
| -41% | -$501K | 0.07% | 261 |
|
|
2020
Q2 | $1.29M | Buy |
4,460
+2,129
| +91% | +$577K | 0.18% | 127 |
|
|
2020
Q1 | $555K | Buy |
2,331
+1,158
| +99% | +$266K | 0.08% | 270 |
|
|
2019
Q4 | $257K | Sell |
1,173
-219
| -16% | -$44.3K | 0.03% | 493 |
|
|
2019
Q3 | $236K | Buy |
1,392
+202
| +17% | +$35.7K | 0.03% | 492 |
|
|
2019
Q2 | $218K | Buy |
+1,190
| New | +$208K | 0.03% | 473 |
|
|
2018
Q2 | – | Sell |
-117
| Closed | -$18K | – | 1353 |
|
|
2018
Q1 | $18K | Hold |
117
| – | – | ﹤0.01% | 1021 |
|
|
2017
Q4 | $18K | Buy |
117
+80
| +216% | +$11.8K | ﹤0.01% | 1022 |
|
|
2017
Q3 | $6K | Buy |
+37
| New | +$5.57K | ﹤0.01% | 1074 |
|
Other funds holding VRTX
VCM
VPM
IHT Wealth Management's VRTX Position: Q1 2026 in Review
IHT Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q1 2026, buying an estimated $109K and bringing the position to 1,697 shares worth $758K. The position accounts for 0.02% of the portfolio, ranked #668.
IHT Wealth Management first reported a position in VRTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $1.29M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- IHT Wealth Management held 1,697 shares of Vertex Pharmaceuticals worth $758K as of Q1 2026.
- IHT Wealth Management bought 234 Vertex Pharmaceuticals shares in Q1 2026, an estimated $109K.
- Vertex Pharmaceuticals made up 0.02% of IHT Wealth Management's portfolio in Q1 2026, its #668 holding.
- IHT Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 30 quarters since.
- IHT Wealth Management's Vertex Pharmaceuticals position peaked at $1.29M in Q2 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on IHT Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.